Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC 0151-0000-0000 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| NNC 0151-0000-0000 i.v. | EXPERIMENTAL | Dose escalation trial |
| NNC 0151-0000-0000 s.c. | EXPERIMENTAL | Dose escalation trial |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC 0151-0000-0000 | DRUG | Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period |
| placebo | DRUG | Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period |
Inclusion Criteria: * CZ: Age between 18 and 65 years (both inclusive) * A diagnosis of rheumatoid arthritis of at least three months before entry in trial * Active rheumatoid arthritis (RA) * Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before ...
NNC 0151-0000-0000 is an investigational small molecule being developed for inflammation. It has been studied in conditions including rheumatoid arthritis and systemic lupus erythematosus. The drug is in Phase 2 clinical development and is not approved for any use.
NNC 0151-0000-0000 is an anti-C5aR antibody, meaning it targets the C5a receptor. This receptor is involved in the complement system, which plays a role in inflammatory responses. By targeting C5aR, the drug aims to modulate inflammation in conditions like rheumatoid arthritis.
NNC 0151-0000-0000 is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in inflammatory conditions.
NNC 0151-0000-0000 is in Phase 2 clinical development. It has completed two trials: a Phase 2 trial in rheumatoid arthritis and a Phase 1 dose-escalation trial in healthy subjects. The drug is investigational and has not received FDA approval.
NNC 0151-0000-0000 has been studied in two completed trials. NCT01223911 was a Phase 2 multiple dose trial in subjects with rheumatoid arthritis, enrolling 34 participants across several European countries. NCT02151409 was a Phase 1 dose-escalation trial in healthy male subjects, enrolling 60 participants in the Netherlands.
Yes, NNC 0151-0000-0000 is an anti-C5aR antibody. This is confirmed by the title of its Phase 1 trial, which describes it as an anti-C5aR antibody. The drug targets the C5a receptor to address inflammatory conditions.